74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Simulations Plus Inc
Closed
SectorHealthcare
14.52 2.11
Overview
Share price change
24h
Min
14.42
Max
14.6
Income | 3.9M 4.5M |
|---|---|
Sales | 5.9M 24M |
EPS | 0.35 |
Dividend yield | 0.48 |
Profit margin | 18.669 |
Employees | 212 |
EBITDA | 4.9M 7.2M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +9.89% upside |
Dividend yield Sector Avg | 0.48% 2.24% |
|---|---|
Next Earnings | 13 Jul 2026 |
Market Cap | 51M 302M |
|---|---|
Previous open | 12.41 |
Previous close | 14.52 |
News Sentiment
By Acuity
26%
74%
88 / 348 Healthcare
Simulations Plus Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Simulations Plus Inc Forecast
Price Target
By TipRanks
9.89% upside
12 Months Forecast
Average 16 USD 9.89%
High 16 USD
Low 16 USD
Based on 3 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.
Sentiment
By Acuity
88 / 348 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Live chat